SOLICITATION NOTICE
A -- Randomized Controlled Trial of Intimate Partner Violence
- Notice Date
- 3/23/2012
- Notice Type
- Presolicitation
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, Centers for Disease Control and Prevention, Procurement and Grants Office (Atlanta), 2920 Brandywine Road, Room 3000, Atlanta, Georgia, 30341-4146
- ZIP Code
- 30341-4146
- Solicitation Number
- 2012-N-14285
- Archive Date
- 4/22/2012
- Point of Contact
- Vallerie M Redd, Phone: 770-488-2845
- E-Mail Address
-
gfj3@cdc.gov
(gfj3@cdc.gov)
- Small Business Set-Aside
- N/A
- Description
- The Centers for Disease Control and Prevention (CDC), National Center for Injury Prevention and Control (NCIPC), intends to award a sole source contract to the Hektoen Institute for Medical Research, 2240 W. Ogden Ave., 2nd Floor, Chicago, IL 60612 for the acquisition of the Randomized Controlled Trial (RCT) of Intimate Partner Violence (IPV) Three Year Follow-up. The statutory authority for this sole source acquisition is 10 U.S.C 2304(c)(1) in accordance with FAR Part 6.302-1- only one responsible source and no other supplies or services will satisfy the agency requirement. The NAICS code for this procurement is 541712, Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology), Size standard 500. The period of performance for this procurement is 24 months. The purpose of this acquisition is to conduct a review of the medical records of participants enrolled in the Randomized Controlled Trial (RCT) for Routine Screening for Intimate Partner Violence (IPV) for the three years after enrollment to establish and compare the number and type of diagnoses of ambulatory and emergency room visits, and hospitalizations by study group. This project will also establish the number of deaths and type of diagnoses occurring among the RCT of IPV screening participants within a two-year period from time of enrollment. Considering the magnitude and severity of intimate partner violence (IPV), and the potential role health care providers could play in reducing its serious consequences, numerous professional and health care organizations have recommended routine screening of women for IPV in primary care settings. However, various systematic reviews of the literature have not found evidence on which to base this recommendation. This lack of evidence led an expert panel, convened by the CDC in February of 2005, to recommend that a randomized controlled trial be conducted to establish the effectiveness of screening on women's health. As a result, in 2008, CDC contracted with the Hektoen Institute for Medical Research to conduct the first Randomized Controlled Trial of Routine Screening for Intimate Partner Violence. This acquisition builds on the previous RCT. Conducting a three-year follow-up focusing on morbidity and two-year follow-up of mortality will provide stronger evidence for or against the effectiveness of screening of women in primary care settings for IPV. Hektoen is the administrative agent for research awards to John H. Stroger Hospital (flagship hospital of Cook County Bureau of Health and Hospital Services) investigators. Hektoen obtained informed consent forms from 2,700 participants for the RCT. These informed consent included permission to access participants' medical records and was approved by both CDC IRB and Cook County Bureau of Health and Hospital Services IRB. Therefore, Hektoen Institute for Medical Research is the only one that can meet the project requirements. In addition to the fact that only the researchers appearing on the informed consent approved by the IRBs have permission to access the IPV screening RCT participants' medical records, Hektoen has ample experience in conducting medical record review. Lastly, providing participant's identifying information to another vendor would violate confidentiality agreements established in the informed consent. Therefore, to conduct a longer follow-up of a screening intervention would require a new RCT which, given the requirements to obtain IRB and OMB approvals and the need for pilot testing procedures, would mean having results approximately six years from now at a cost almost eight times greater than the current cost. As a result of this synopsis, no competitive solicitation will be posted on FedBizOpps. We will issue only one solicitation to the Hektoen Institute for Medical Research However, all responsible sources that believe they can meet these requirements may submit their capabilities/qualifications statement to provide the services to Vallerie Redd via email ONLY at gfj3@cdc.gov with the solicitation number 2012-N-14285 referenced in the subject line NO LATER THAN April 7, 2012. A determination by the Government not to compete this proposed action will be based on responses to this notice and are solely within the discretion of the Contracting Officer. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/CDCP/PGOA/2012-N-14285/listing.html)
- Place of Performance
- Address: Contractor Facility, United States
- Record
- SN02704331-W 20120325/120323234844-347c9e079fb6d0546ce3fd85b21821ce (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |